LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akcijų sąrašas・Editas Medicine Inc

Editas Medicine Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.19 7.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.01

Max

2.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	28M -25M
Pardavimai	4M 7.5M
Pelno marža	-332.984
Darbuotojai	246
EBITDA	27M -22M

Rekomendacijos
By TipRanks
Rekomendacijos	Parduoti
12 mėnesių prognozė	+86.05% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-65M 210M
Ankstesnė atidarymo kaina	-5.16
Ankstesnė uždarymo kaina	2.19

Naujienos nuotaikos

By Acuity

50%

158 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.33 / 1.54 Palaikymas ir pasipriešinimas

Editas Medicine Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-03 18:43; UTC

Svarbiausios naujienos

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026-03-03 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026-03-03 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026-03-03 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-03 22:38; UTC

Svarbiausios naujienos

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026-03-03 22:16; UTC

Uždarbis

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026-03-03 22:09; UTC

Uždarbis

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026-03-03 22:06; UTC

Uždarbis

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026-03-03 22:05; UTC

Uždarbis

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026-03-03 22:03; UTC

Uždarbis

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Tech, Media & Telecom Roundup: Market Talk

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-03 21:45; UTC

Svarbiausios naujienos

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026-03-03 21:37; UTC

Uždarbis

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026-03-03 21:26; UTC

Svarbiausios naujienos

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026-03-03 20:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026-03-03 20:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026-03-03 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold and Silver Drop as Energy Surges -- Market Talk

2026-03-03 18:43; UTC

Uždarbis

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026-03-03 18:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026-03-03 18:14; UTC

Uždarbis

How Long Can Anthropic Play Defense? -- WSJ

2026-03-03 17:41; UTC

Svarbiausios naujienos

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026-03-03 17:36; UTC

Svarbiausios naujienos

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026-03-03 17:28; UTC

Įsigijimai, susijungimai, perėmimai

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Akcijų palyginimas

Kainos pokytis

Editas Medicine Inc Prognozė

Kainos tikslas

By TipRanks

86.05% į viršų

12 mėnesių prognozė

Vidutinis 4 USD 86.05%

Aukščiausias 4 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Editas Medicine Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Parduoti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Editas Medicine Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.33 / 1.54Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.